Merck has announced that the Biologics License Application for V 503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been...
Zealand Pharma announced it has entered into an asset purchase agreement with MannKind Corporation ( to sell the V-Go insulin delivery device for $10 million and additional sales-based milestones).
At three years, the Promus Element everolimus eluting stent, from Boston Scientific, continued to demonstrate advantages for CAD patients over...
Merck Inc.,, known as MSD outside the United States and Canada, announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V 590 and V 591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK 4482 and MK 7110.
The FDA on 18 September 2012 approved the somo-v Automated Breast Ultrasound System (ABUS) from U-Systems Inc., which is the...
New findings from the DUAL V phase IIIb clinical trial showed greater improvements in treatment-related satisfaction and patient-reported physical health...